Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Disruptive Dynamics in Healthcare and the Impact on Medtech
The evolution of the U.S. healthcare industry has been a matter of both regulatory change principally catalyzed by the Affordable Care Act (ACA) and its imperative to shift the industry's business incentives from ?volume to value" in addition to transformation compelled by macro-trends like the rapid advancement of technology and big data and their increasing accessibility to individual consumers. The impact on medical device, or medtech, companies is multifold: they are experiencing the pressure of reimbursement cuts indirectly through interactions with their customers, and they are also witnessing out-of-industry companies like Apple and Google testing capabilities in the traditional medtech domain.
Consolidation between and among payers and providers, who represent key customers of medtech, has contributed to parallel consolidation trends among device companies. Greg Davis notes that medtech companies have observed intense provider consolidation and reacted accordingly: ?Medtech companies are continuing to consolidate at a rapid pace, making a scale and size play. Especially as payers and providers grow more consolidated, this approach helps the medtech players remain at the negotiating table, by enabling them to talk about a wider range of products." Moreover, Rick Anderson points out that device companies, particularly those in commodity categories, are ?facing tremendous pricing pressure" from payers and providers, and have reacted by leveraging acquisitions in an effort to, ?get too big to ignore they want to ensure that the payers and health systems and integrated delivery networks have to pay attention to them."
The shift in traditional purchasing dynamics for devices has also impacted how medtech companies approach selling, as they increasingly need to engage a larger stakeholder group and acknowledge the emerging emphasis on value. According to Davis: ?for decades, the med device industry has been focused on the physician as the key decision maker. But now many physicians are employed by hospitals; while they're still at that negotiating table, they're only a single voice at the table today." Additionally, medtech companies are responding to the needs and preferences articulated by their customer base and regulators by increasingly considering broader contracting arrangements that cover larger product sets and reflect the emphasis on value and risk-sharing that is ubiquitous today among payers and providers. Davis says that device companies are expressing ?interest in getting into the services side of the business; they're talking about developing more complete packages that might mean they get paid based on the continuum of care, rather than for a particular implant or other device."
That said, Rick Anderson suggests that there's an element of dissonance between what many medtech companies communicate publicly versus carry out in day-to-day business operations: ?They're saying all the right things and claim to be figuring out population health, but the absolute truth is that most are really doing nothing about it in fact, if they were really to enable population health initiatives, it would disrupt their business model; having to deal with things like risk-sharing would be inconsistent with how they sell their products."
Medtech companies' lack of substantive action on the population health front has facilitated the entrance of out-of-industry players like IBM and Alphabet (Exhibit 1), who, in Anderson's words, are ?looking over the fence at healthcare, and saying, ?we can innovate in that space.'" While medtech companies collect and manage enormous amounts of data, Anderson and Davis suggest that technology companies like IBM Watson and Verily are the driving force behind new data analytics partnerships with established medtech players like Medtronic and Johnson & Johnson. Anderson says, ?the people who are really doing something on this front are the data people, like those at Verily; it's those tech companies who really understand the value of the data, and medtech is chasing rather than leading those partnership conversations." While early examples of these partnerships like Verb Surgical and Galvani Bioelectronics still have yet to launch major product offerings, Anderson and Davis agree that the wealth of data housed in the medtech space is likely to continue attracting the attention of out-of-industry innovators.
Positioning for Success Emerging Models For Medtech Dealmaking
In reviewing industry dynamics and the deal activity of medical device companies, Anderson and Davis describe a cast of archetypes that are likely to emerge as various players leverage different strategies and more specifically, types of deals to cope with industry-wide disruption. Anderson observes, ?bigger companies are deciding, as we speak, whether to be ?too big to fail' or to be technology innovators." He comments that the largest global players like Johnson & Johnson are more likely to choose the former, because, ?they're giant players with an unmatched global footprint; their strategy will be to occupy categories where they can win with scale." Companies like these, in Anderson's opinion, may invest modestly in innovation, but generally will play a consolidator role, operating under the assumption that ?they can buy whatever they want at whatever price."
Anderson also describes an alternative approach, in which companies like Siemens, GE, and Philips seek to vertically integrate and make targeted investments in particular services and therapeutic areas. The key to making this a winning strategy, according to Anderson, is to pick the right verticals that are well-positioned for innovation.
Underpinning both of these approaches is a heavy preference for acquisition on the part of traditional medtech companies. In Davis' words, ?large medtech companies have historically relied on a model of buying innovation from small companies, and then throwing it into their big company sales engines." However, both Anderson and Davis point out the pitfalls of this attitude, commenting, ?after the financial crisis, throughout 2008-2009, there was almost zero startup activity in medtech the largest hole ever in our industry is playing out right now, and the big companies are complaining that there's nothing to buy." Anderson says, ?the biggest medtech players are blindly going about what they've been doing, thinking the ecosystem will produce more companies when in fact, the tech folks like Qualcomm and Google see this as an opportunity to come in and disrupt their businesses."
Creative Approaches to Medtech Deals
Faced with a shortage of conventionally attractive acquisition targets, some medtech companies are turning to partnerships and creative deal terms to alleviate the stress of investing in early-stage, high-risk startups. Anderson remarks that while large device companies are ?starving for growth," many remain reluctant to make investments that are not accretive on day 1. Moreover, there's real risk of crushing new startups with heavy corporate structures, policies, and management. That said, Anderson argues, ?there's an awakening happening these companies are realizing that they can support off-balance sheet R&D units, and then leverage their global footprint to sell and share margin."
Arguably the most creative of these partnership structures are what Anderson calls ?build and buy" deals, a form of synthetic joint venture or phased acquisition between a startup technology company and its venture capital or private equity partners on the one hand, and an established medtech player on the other. The parties pre-agree to an overall partnership timeframe, development and other milestones, incremental funding commitments, exit ramps, and other key deal terms. As the partnership launches and progresses, the startup company gets access to capital in pre-agreed portions by way of convertible debt, off of the larger company's balance sheet as it achieves the predetermined milestones. Those milestones pertain not only to proving and scaling the technology in question, but also may include integrating the startup organization and its capabilities into the larger company's structure and product suite. If successful, the larger company will officially acquire the startup at the end of the programmed collaboration period, having already proven out the technology, tested the relationship, and proactively addressed the logistics of integration.
There are several clear benefits to this type of deal structure. In leveraging a ?build and buy" deal, large medtech companies have an opportunity to more exhaustively vet and nurture emergent technologies before taking major hits to their P&Ls. Startups receive the funding they need, but in Anderson's words avoid being ?tinkered to death" by the corporate structure and processes of an established medtech company. Looking ahead, Anderson believes that this type of collaborative transaction will be an appealing mechanism to de-risk key investments while fostering critical innovation in the medtech ecosystem.
Like most of the healthcare industry, Davis and Anderson agree that the medtech sector today is in a transitional period, anticipating a ?tsunami" of digital innovation and beginning to leverage collaborative deals as a means to capitalize on it. The companies best positioned to succeed will be those who commit meaningfully to innovation and are willing to flex collaborative partnership muscles that have been neglected by medtech players historically.
Read the full story at http://www.prweb.com/releases/2017/10/prweb14763875.htm.
Good article. Spells out the situation the large med device companies are in as well as companies like Titan. Hard to believe we won't be partnering with someone big along the way ....
http://itbusinessnet.com/article/Water-Street-Partner-Interview-with-PTV-Healthcare-Capital-and-MedCelerate:-Playing-to-Win-in-MedTech-Dealmaking-5175547
Should have closed at .28 today. Small trade at the close brought us to .27
All good though. Nice trading today!
Broke one million shares traded again today. That marks 16 trading days in a row of at least one million shares traded, and the 6 trading days preceding those had significant volume as well, at least 500K. One month chart looks good, need to break above this .28 resistance and get into the .30 level. Release more good news Mac. Let's go!
Definitely a new one to our stock. Just like DBOX who came around a few weeks back for a bit. The ones I see the most for us are ETRF, CSTI, NITE, INTL, CANT, CDEL and then ARCA of course. Every now and then another MM comes around for a bit, likely because the brokerage firm uses that particular MM when a client buys or sells stock.
BigT is this a new MM? Don't remember this one...MCAP
https://www.mcapmarkets.com
According to morningstar, another fund has picked up shares of the mighty titey! :
Dynamic Venture Opportunities Sr II.
I too am surprised the market is open, and even more surprised we have this much volume already today and with a 10% pop. Most action appears to be buyers at the Ask again today. I too am hopeful we break into the 30s by the end of the week, with possible more good news on tap to be shared with us investors soon. Go Titan!
Should we be concerned that the contact for that pr firm is Mark Twain?
My mistake, I assumed since you were inquiring on how to go about it you weren't as sophisticated a trader to know about currency arbitrage...not that I'm that sophisticated...I always guess wrong about currency swings so I avoid them at this point. I know about these things just don't practice them. Best of luck to you, let us know what you find out.
I'm optimistic we could break over it this week even without news given today's action on what is supposed to be a weak day given holidays, etc. It looks like the word is still spreading and new buyers are coming in.
News should do a lot more than just break .30.
It wasn't too long ago we wouldn't have even been mentioned. A lot has changed since McNally came on board. Thank goodness!
ISRG OS now at 112m.
A RS by Titan will put us far below that number.
Our SS isn't all that bad all things considered.
Nice find! Love how we are listed first on here!
"Major Player"
https://www.openpr.com/news/761387/Global-Medical-Robotics-Market-Forecast-Trends-and-Segmentation-2016-2024.html?lipi=urn%3Ali%3Apage%3Ad_flagship3_feed%3Bih439CdcRzuv2Y5gpvt3Aw%3D%3D
Introduction of robotic nurses is improving the patient care service segment. Robots which can lift up or set down patients from bed or wheelchair is gaining immense popularity. RIBA (Robot for Interactive Body Assistance) which is developed by Japanese research institute RIKEN and Tokai Rubber Industries is an innovative solution for providing quality services to patients. Recent advancement in the medical robotics market is shaping the future of robotics in medical services. Global medical robotics market segmentation has been carried out on the basis of product type such as surgical robots, rehabilitation robots, non-invasive radio-surgical robots and hospital & pharmacy robots. Increasing adoption of surgical robotic systems in hospitals is raising the demand for surgical robots across the globe. Surgical robotics segment accounted for 42% of market share in 2016. Our market research report on medical robotics market compasses latest insights about the market, our domain expert opinion to get you ahead in the global competition.
Request for TOC@ www.goldsteinresearch.com/toc-request/global-medical-robo...
Market Segmentation
Global Medical Robotics Market is categorized on the following basis:
• Based on Product Type
o Surgical Robots
o Rehabilitation Robots
o Non-invasive radio-surgical Robots
o Hospital & Pharmacy Robots
• Based on Application
o Neurology
o Orthopedics
o Cardiology
o Laparoscopic
o Other (Gynecology, Nanomedicine)
• Based on Country
o North America (U.S. & Canada)
o Latin America (Brazil, Mexico & Rest of Latin America)
o Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE)
o Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia)
o Middle East & Africa (GCC, South Africa, North Africa, RoMEA)
o Rest of World
Send Us Sample Request@ www.goldsteinresearch.com/request-sample/global-medical-r...
“Global Medical Robotics Market 2024” contains detailed overview of the global medical robotics market in terms of market segmentation by product type and by application.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis.
Global medical robotics market report also provides competitive outlook of some of the major players of the global medical robotics market which includes profiling of companies such as Titan Medical Inc., Medtronic, Stryker Corporation, TransEnterix Inc., Medtech, Abbot Diagnostics, Aurora Biomed, Irobot Corporation, Intuitive Surgical, Hansen Medical, Mazor Robotics, Kirby Lester LLC, Accuray Incorporated, Ekso Bionics Holdings, Inc., Hocoma AG, Omnicell, Inc., CareFusion, Biotek Instruments and Rewalk Robotics. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments.
Overall, report represents medical robotics market trends that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Browse Full Market Report@ www.goldsteinresearch.com/report/global-medical-robotics-...
About Goldstein Research
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts. Backed up by reliable research and impactful statistics, our business solutions empower our clients to grow at a fast pace despite unsettling fluctuations in the market. We believe in vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.
To know more information please ask to our analyst@ www.goldsteinresearch.com/ask-to-analyst
99 Wall Street ,Suite No-527, New York, NY 10005
Contact for more Info:
Mark Twain
(Global Sales Head)
USA: + 1-646-568-7747
Canada: 1-437-886-1181
UK: +44-203-318-6627
sales@goldsteinresearch.com
www.goldsteinresearch.com
This release was published on openPR.
Not reverse...3:1 split; stockholders have 3X as many shares at 1/3 the price.
New IP firm listed on most recent patent.
http://www.smart-biggar.ca/en/index.cfm
Depending on overall circumstances, currency exchange issues are not always negative and can potentially work in one's favor as well. Thank you for suggesting my broker, but I am looking for a public on-line source for Canadian stock and warrant quotes. I had been using marketwatch.com but lately I've had trouble with the site. I haven't done new research yet, I thought someone on this board might have already done so and could save me the trouble.
It's funny how a few weeks ago, half a million shares traded would have looked like a huge day, and now it seems like peanuts... I assume lots of people aren't at work due to the holiday; pretty quiet here on the board as well. I'm almost surprised the market isn't closed for Columbus Day/Indigenous People's Day/Displaced Spotted Newt Acknowledgement Day/Capitalist Atonement Day... or whatever fictitious nouveau pseudo-holiday they want to fabricate next in order to hijack another piece of our country's history. But I digress - once again.
At least PPS is moving in the right direction at the moment. My September IRA statements came in and looked really really nice, thanks mostly to our Little Stock That Could. (Chug Chug). The post-split ISRG stock at around $350/share is starting to look more vulnerable now! Go Titan!
Still on pace for 1m+ today...
Bank holiday in the US and holiday in Canada I believe. Couldn't transfer funds to my E*TRADE account. Also heard there is/was a problem with Ameritrade today. Nice move up nonetheless. Hoping to get news tomorrow.
Looks to be low volume so far but the PPS seems to have an upward stability about it. I'd love to break .30 this week. Anyone think we get any news this week?
I'm going to go out on a limb and venture your broker. ywia
But seriously, if you are a us citizen why do you want to convert your currency to CAD buy shares? Unless TSX takes euro dollars? You'd have to convert it back and will necessarily lose money in the transaction in both directions.
Anyone know where I can get trading quotes on TMD and on the full series of Warrants? TIA
Single
Port
Prostatectomy
I think Titans three choices of surgical indications that they are going for FDA approval were choices because of there simplicity in both programming the robot and learning curve for surgeons. I believe the pivotal indication in ISRGs rise to fame was prostatectomy as it pretty much eliminated sexual dis function by not impacting the nerve bundles that surround the prostate. This sealed the robots fate as the choice of most patients and from a marketing stand point hospitals needed the Da Vinci, in spite of its money loosing expenses, just to keep the patient. I am guessing that is why Dr. Patel is part of our team as once we get the FDA's blessing that prostatectomy will be one of the next indications that Titan goes for. Do you think the hospitals would be interesting in a robotic surgery platform that actually fulfills there marketing needs and allows them do these surgeries while hopefully turning a profit? Hell Yes!!
Time to put some more good news out McNally!
Let’s not loose this great momentum
Makes sense about the training. I think the broad indication path is the smarter way to go.
I think they did, but after they had multiple discussions with physicians around the country, they decided it would be best to go after multiple applications. Also, they wouldn't be able to develop software or training for other procedures because it would be off label so the off label usage would be minimal.
I agree. Would need to have significant design changes IMO.
The only entry points the are through anal or mouth, if you don't believe me watch the video they say it
I'm not sure how this will ever do a major case...maybe bladder and cervical cases...but it doesnt look capable of doing a hysterectomy, prostatectomy, partial nephrectomy, etc...
Hmmmmm.....getting closer.
RAYNHAM, Mass., Sep. 28, 2017 - Medrobotics Corp., a medical robotics company, today announced that it submitted an application to the FDA for clearance of a flexible transabdominal robotic scope proposed to visualize anatomy in the thoracic and abdominal cavities. This submission reaffirms the Company’s commitment to develop products for single-port general, gynecological, and urological surgeries.
are we the only ones getting a pop from the stock or does titan also get a pop from any outstanding shares they may be holding.
I agree with your assessment, it ultimately better to have broad indications approved. But I wonder what was the rationale behind a single indication submission? Since surgeons may take the liberty to use off label, do you think they anticipated a quicker FDA approval as single indication, then surgeons could just use as needed on other procedures?
The timeline delay that you are referring to is because they were only going after 1 indication...gall bladders. In hindsight it was a good thing they changed course.
Is it still the case that their next MD&A should be released next week? I think they get 45 days to release quarterly results after the end of the quarter, if I'm not mistaken.
Different times...all that was there of SPORT in those days was this:
https://abm-website-assets.s3.amazonaws.com/mdtmag.com/s3fs-public/XimedicaTitanImage%202_hi.jpg
I think we're way past any dramatic changes in timelines now.
Wonder if Titan will issue yet another dramatic alteration in their timelines? I think about getting back in but after the shift from Amadeus to Sport and then the real gut punch when we pushed everything back again pursuing more indications I'm just not sure. What's next? Are we still lacking foresight?
Indeed! Glad I loaded up under .20
Now that SPORT is at the other two testing sites. When news starts coming out from those sites like Nicholson, the demand should increase exponentially.
I believe the demand is building for this stock and we will continue on an upwards trajectory with minor pullbacks along the way.
Do you think today we entered a C pattern, and will close towards $.30?
No. Stock could open up then sell off. Just never know. But MMs know demand, so if the bid is building they will move it up.
Titan Medical
January 10, 2022 Titan Medical Corporate Presentation
https://d1io3yog0oux5.cloudfront.net/_101e2d94c73b26bc133246c537736f29/titanmedicalinc/db/1086/9873/pdf/Titan+-+IR+Presentation+-+Q1+2022+FINAL.pdf
*200+ patents issued or pending
Surgeon Feedback From Initial Clinical Testing:
Ricardo Estape, M.D., a robotic gynecologic oncology surgeon from South Miami Gynecology Oncology Group who specializes in robotic single port surgeries, said, “The SPORT Surgical System performed beyond my expectations and I was able to complete a variety of critical surgical tasks with the necessary dexterity and precision through a single incision. The robotic instruments provided the necessary articulation, range of motion and rigidity along with 3D high-definition video on the flat panel monitor that allowed me to complete the surgery in a comfortable posture. This could be a game changer in gynecological surgery.” SEE VIDEO
Eduardo Parra-Davila, M.D., a robotic colorectal surgeon at Florida Hospital who has trained thousands of surgeons worldwide on robotic surgery, commented, “Single port surgery without robotic assistance is not easy and yet it remains highly beneficial because of the desire to have fewer ports. It’s all about robotic articulation delivered through a single incision that allows for the reach, necessary angles and multi-quadrant access to treat diseases in colorectal surgeries. The SPORT Surgical System has the promise to become a valuable tool for all robotic surgeons looking to do single port surgery in the future.” SEE VIDEO
Arnold Advincula, M.D., Chief of Gynecologic Specialty Surgery at Columbia University and an expert in robotic surgery, said, “After using the SPORT system, I am more convinced that single-port robotic surgery could become a reality for many patients. Previous approaches to single-incision surgery have been limiting and ineffective. The SPORT system demonstrated that it can not only address those limitations, but it may also provide some unique capabilities for enabling a variety of gynecologic surgeries through a single incision. The future of single-port robotic surgery is bright and I am excited to actively participate in this journey with Titan Medical.”
Vipul Patel, M.D., a world-renowned robotic urology surgeon from the Global Robotics Institute at Florida Hospital and the only surgeon in the world to have completed 10,000 robotic prostatectomies, said, “Although multi-port robotic prostatectomy is currently the standard of care in urology, single port robotic surgery could be the next frontier in urology and other surgical disciplines. It was exciting for me to use Titan Medical’s SPORT system at Florida Hospital Nicholson Center. The technological capabilities of the SPORT system are very encouraging and the early success in establishing feasibility is an important step in the right direction.”
William Burke, M.D., a gynecologic oncologist at Stony Brook University Hospital with extensive robotic surgery experience, commented, “Having completed thousands of multi-port robotic surgeries over several years of practice, I was pleased with the capabilities of the SPORT system that eased my transition from a multi-port approach to single-port robotic surgery. The workspace, access and ease of use while maintaining critical multi-port robotic features such as multi-articulated instruments and high-definition 3D visualization through a single incision, are important factors in transitioning from multi-port to single-port robotic surgery. I must say that the SPORT system, with its sophistication, makes a highly compelling case for single-port robotic surgery.”
Lee Swanstrom, MD, FACS, Chief Innovation Officer of IHU Strasbourg, said, “I was pleased with my first experience with the SPORT system for applications in abdominal procedures. There are many patients undergoing general surgical procedures who could greatly benefit from a reduced number of incisions. Single-port robotic surgery can be a truly enabling solution for patients and surgeons alike, and it is exciting to see that the SPORT system takes us much closer to that possibility.”
Jelle Ruurda, MD, a gastrointestinal and oncologic surgeon at University Medical Center Utrecht, who has several years of robotic surgery experience, commented, “Many oncologic general surgery procedures require specimen retrieval at the end of the procedure. These procedures are natural applications for single-port robotic surgery. My first operation of the SPORT system in a preclinical environment was very exciting, and the system shows great promise for future clinical use. I look forward to the opportunity to work together with Titan Medical to evolve a single-port robotic surgery option for my oncology patients. Based on this first experience, I am confident that single-port robotic surgery has a bright future”.
Eric Barret, MD, a world-renowned robotic urologic surgeon at Institut Mutualiste Montsouris, said, “Having performed many single-incision robotic surgeries with flexible, non-wristed and crossed-over instruments, my first experience with the SPORT system was exceptional. The SPORT system addresses many limitations of previous laparoscopic and robotic single-incision surgery approaches, and holds significant promise for meaningful use in urologic applications.”
The SPORT Surgical System is a versatile single incision advanced robotic surgical system that features state-of the-art multi-articulated instruments with single-use replaceable tips, 3D high definition visualization on a flat-screen monitor, ergonomic open workstation and a single-arm mobile patient cart for ease of set up while enabling broad applications of single and multi-quadrant surgeries previously not possible with current robotic solutions.
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2019. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation. http://www.titanmedicalinc.com/
Interim President & CEO
In his over 10 years at Zephyr, Mr. Cataford was able to grow the team to over 65 people, clear class II medical devices through both 510 (k) and De Novo FDA approval paths and build a 13485: 2016 certified manufacturing facility. Zephyr successfully closed on two joint ventures with established dental technology companies raising over $20 million from a combination of strategic and private investors. He brings significant high technology and medical device company experience and is a key contributor to strategy, M&A, corporate finance, governance, team building and empowerment and scale. Over the last 25 years, Mr. Cataford has also served as independent corporate director on a number of TSX, TSXV and NASDAQ company boards including: Sierra Wireless, Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Mr. Cataford has a Bachelor of Science degree in Mechanical Engineering from Queen’s University, an MBA specializing in Finance and International Strategy from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College, Rotman School of Business at the University of Toronto.
Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.
Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.
Dr. Boyd is a Professor of Surgery and Director of Robotics and Biosurgery at the University of California Davis. He is Head of Adult Cardiac Surgery and Surgical Director of the Transcatheter Valve Program. He is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems. He specializes in minimally invasive cardiac and robotic-assisted heart surgery. Dr. Boyd completed the world’s first closed-chest, beating-heart coronary artery bypass surgery using a robotic system in 1999. Prior to his appointment as a professor of surgery at UC Davis Health System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. As the author of more than 70 peer-reviewed, journal articles, Dr. Boyd’s research interests include cardiac tissue regeneration using extracellular matrix/stem cells, new techniques for robot-assisted minimally invasive coronary artery revascularization, valve surgery and tele-surgery. He is a graduate of Carleton University in Ottawa, Canada and obtained his medical degree from the University of Ottawa, Canada.
Dr. Litwin trained in General Surgery at the University of Saskatchewan, and completed a hepatobiliary fellowship at the University of Toronto. He was an early pioneer in laparoscopic surgery, having performed the first laparoscopic cholecystectomy in Western Canada in 1990 and the first laparoscopic colectomy in Canada in 1991. He was a leader in educating a large number of surgeons across Canada in basic and advanced laparoscopic techniques. During the early advent of minimally invasive surgery, he innovated new laparoscopic approaches to the spine and aorta, and he participated in the development of HandPortTM, a hand assist device for laparoscopic surgery. In 1993, Dr. Litwin became the Director of Minimally Invasive Surgery at the University of Toronto. In 1997, he moved to the University of Massachusetts as Chief of Minimally Invasive Surgery. Since 2004, he has been Chairman of Surgery at the University of Massachusetts Medical School and UMass Memorial Medical Center, one of the largest Academic Health Sciences Centers in Massachusetts. There, he continues to practice minimally invasive surgery of the abdomen in addition to his administrative role.
Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.
Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |